Published in Gene Therapy Weekly, October 3rd, 2002
In a collaborative study carried out by investigators from the United States and Ireland, interleukin (IL)-1 receptor antagonist (IL-1 RA) gene therapy was used to stem corneal neovascularization and change inflammatory cytokine profiles in conjunctivalized cornea murine models.
Animals were subjected to corneal injury just before receiving therapy. "Total corneal epithelial and limbal debridement was performed with a combination of alkali and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.